Sylvan, a Beijing, China-based producer of fungal biotechnology options, acquired an funding from Novo Holdings.
The quantity of the deal was not disclosed. KKR will stay the corporate’s majority shareholder.
The brand new capital will help Sylvan’s enlargement by enabling elevated manufacturing capability, upgraded R&D infrastructure, and penetration into high-growth markets, notably in Asia. Sylvan can even profit from Novo Holdings’ intensive community and sector experience to additional strengthen its place within the international mushroom spawn market and develop new high-impact bio-products, resembling fungi-based supplies, biopesticides, and dietary dietary supplements.
Based in 1932 and led by Jackie Qi, CEO, Sylvan is a big mushroom spawn and fungal biotechnology firm that creates sustainable options to deal with international challenges in meals, well being, agriculture, and supplies. Right now, the corporate operates a number of manufacturing services all over the world and serves prospects throughout 65 international locations.
FinSMEs
03/04/2025
